DelveInsight's Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

CheckMate 9DW adds a third immunotherapy regimen to the therapeutic repertoire for first-line treatment of unresectable hepatocellular carcinoma. Although cross-trial comparisons are challenging, ...

Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), the most ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year ...

Senti Biosciences, Inc.’s SNTI share price has dipped by 6.26%, which has investors questioning if this is right time to buy.

A PDF version of this document with embedded text is available at the link below: US012203862B1 (12) United States Patent ...

By analysing DNA from blood samples, Tvaster Genkalp is working to make cancer diagnostics more accessible, accurate, and ...

PD-1 blocking antibody and CTLA-4 blocking antibody As first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma Opdivo + Yervoy Approved as First-Line Tx for HCC ...

Aditya Shreenivas, MD, MS, discusses findings from the clinical trial supporting the FDA approval of penpulimab in nasopharyngeal carcinoma ... versus chemotherapy and placebo as a first-line ...